Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.44M Sell
3,667
-2,243
-38% -$768K 0.11% 210
2026
Q1
$2.05M Buy
5,910
+250
+4% +$89.1K 0.16% 149
2025
Q4
$1.87M Buy
5,660
+228
+4% +$72.3K 0.16% 147
2025
Q3
$1.59M Buy
5,432
+1,058
+24% +$307K 0.14% 158
2025
Q2
$1.3M Sell
4,374
-194
-4% -$55K 0.14% 170
2025
Q1
$1.27M Buy
4,568
+295
+7% +$87.1K 0.16% 147
2024
Q4
$1.14M Buy
+4,273
New +$1.27M 0.16% 141

Other funds holding AMGN

Sovran Advisors's AMGN Position: Q2 2026 in Review

Sovran Advisors reduced its Amgen (AMGN) stake by 38% in Q2 2026, selling an estimated $768K and leaving 3,667 shares worth $1.44M. The position accounts for 0.11% of the portfolio, ranked #210.

Sovran Advisors first reported a position in AMGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.05M in Q1 2026. 1,543 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Sovran Advisors held 3,667 shares of Amgen worth $1.44M as of Q2 2026.
  • Sovran Advisors sold 2,243 Amgen shares in Q2 2026, an estimated $768K.
  • Amgen made up 0.11% of Sovran Advisors's portfolio in Q2 2026, its #210 holding.
  • Sovran Advisors first reported a position in Amgen in Q4 2024 and has held it in 7 quarters since.
  • Sovran Advisors's Amgen position peaked at $2.05M in Q1 2026.
  • 1,543 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Sovran Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.